Skip to main content

Platforms & Technologies

Auto-injector platform

The Emergard®  auto-injector platform is designed for intramuscular rapid delivery of nerve agent antidotes and other emergency response medical treatments. The auto-injector can address exposure to certain chemical agents by delivering an antidote to those agents after exposure. This platform is designed for self and buddy administration when used in a military setting and for use by emergency medical personnel in the event of civilian exposure. (Auto-injector is not approved by the U.S. FDA)

Auto-injector platform

The Emergard®  auto-injector platform is designed for intramuscular rapid delivery of nerve agent antidotes and other emergency response medical treatments. The auto-injector can address exposure to certain chemical agents by delivering an antidote to those agents after exposure. This platform is designed for self and buddy administration when used in a military setting and for use by emergency medical personnel in the event of civilian exposure. (Auto-injector is not approved by the U.S. FDA)

Hyperimmunes

Emergent has expertise with FDA-approved human and equine plasma products generated for targeted therapy of specific indications. Our hyperimmune specialty plasma product manufacturing platform has been used to create multiple products that have obtained FDA approval, up to a scale of 1000L.

Human Platform – Purified gamma globulin (IgG) containing polyclonal antibodies to specific antigen(s) obtained from human plasma.

Equine Platform – Purified immune globulin fragments derived from polyclonal antibodies to specific antigen(s) obtained from equine plasma.

Hyperimmunes

Emergent has expertise with FDA-approved human and equine plasma products generated for targeted therapy of specific indications. Our hyperimmune specialty plasma product manufacturing platform has been used to create multiple products that have obtained FDA approval, up to a scale of 1000L.

Human Platform – Purified gamma globulin (IgG) containing polyclonal antibodies to specific antigen(s) obtained from human plasma.

Equine Platform – Purified immune globulin fragments derived from polyclonal antibodies to specific antigen(s) obtained from equine plasma.

Antivirals

Emergent's broad-spectrum antiviral iminosugars platform uses a mechanism of action that inhibits a host glycosylation pathway resulting in misfolded viral glycoproteins, subsequently leading to reduced viral infectivity. Enveloped viruses are potential targets, with treatment of acute Dengue illness currently in clinical development.

Antivirals

Emergent's broad-spectrum antiviral iminosugars platform uses a mechanism of action that inhibits a host glycosylation pathway resulting in misfolded viral glycoproteins, subsequently leading to reduced viral infectivity. Enveloped viruses are potential targets, with treatment of acute Dengue illness currently in clinical development.

Antimicrobials

Emergent's EV-035 series of broad spectrum antibiotics have a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains

Antimicrobials

Emergent's EV-035 series of broad spectrum antibiotics have a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains

MVAtorTM

(modified vaccinia virus Ankara vector)

MVAtor is a flexible, proprietary, viral vector platform based on modified vaccinia virus Ankara (MVA) for delivery of protective or therapeutic antigens. MVA was administered to more than 100,000 subjects as a "prevaccine" prior to use of unattenuated vaccinia. We are using MVAtor to develop novel prophylactic and therapeutic vaccines. MVAtor is derived from an MVA strain isolated before bovine spongiform encephalopathy (BSE) was identified.

MVAtorTM

(modified vaccinia virus Ankara vector)

MVAtor is a flexible, proprietary, viral vector platform based on modified vaccinia virus Ankara (MVA) for delivery of protective or therapeutic antigens. MVA was administered to more than 100,000 subjects as a "prevaccine" prior to use of unattenuated vaccinia. We are using MVAtor to develop novel prophylactic and therapeutic vaccines. MVAtor is derived from an MVA strain isolated before bovine spongiform encephalopathy (BSE) was identified.

Trademark Legend
Emergent BioSolutions, Protected by Emergent BioSolutions™, Anthrasil™, BAT®, BioThrax®, Emergard®, MVAtor™, NuThrax™, PreviThrax™, and RSDL® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries.